Q1 2025 EPS Estimates for Omnicell, Inc. Lifted by Zacks Research (NASDAQ:OMCL)

Omnicell, Inc. (NASDAQ:OMCL) – Zacks Research boosted their Q1 2025 earnings per share estimates for shares of Omnicell in a report released on Tuesday, October 1st. Zacks Research analyst U. Biswas now anticipates that the company will earn $0.14 per share for the quarter, up from their previous estimate of $0.13. The consensus estimate for Omnicell’s current full-year earnings is $0.64 per share. Zacks Research also issued estimates for Omnicell’s Q1 2026 earnings at $0.29 EPS and FY2026 earnings at $0.73 EPS.

Other analysts have also recently issued research reports about the company. Benchmark restated a “buy” rating and set a $38.00 price objective on shares of Omnicell in a research note on Monday, July 15th. Bank of America upped their price target on Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a report on Thursday, September 19th. Wells Fargo & Company increased their target price on shares of Omnicell from $26.00 to $30.00 and gave the stock an “equal weight” rating in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. raised their price target on shares of Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a research report on Friday, August 23rd. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $37.83.

Omnicell Stock Performance

Shares of Omnicell stock opened at $42.30 on Thursday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45. Omnicell has a 1 year low of $25.12 and a 1 year high of $46.05. The firm’s 50-day simple moving average is $41.58 and its 200-day simple moving average is $33.12.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.37. The firm had revenue of $276.80 million for the quarter, compared to analysts’ expectations of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The firm’s quarterly revenue was down 7.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.29 earnings per share.

Institutional Investors Weigh In On Omnicell

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in shares of Omnicell by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock worth $165,200,000 after acquiring an additional 80,312 shares during the period. Mutual of America Capital Management LLC raised its holdings in shares of Omnicell by 197.9% during the first quarter. Mutual of America Capital Management LLC now owns 124,600 shares of the company’s stock valued at $3,642,000 after buying an additional 82,774 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Omnicell by 61.3% during the second quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock worth $16,240,000 after buying an additional 228,093 shares during the period. SG Americas Securities LLC bought a new position in Omnicell in the 1st quarter worth approximately $684,000. Finally, Cadian Capital Management LP bought a new position in Omnicell in the 4th quarter worth approximately $2,446,000. 97.70% of the stock is currently owned by institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.